Comparative Pharmacology
Head-to-head clinical analysis: ARBLI versus MANDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARBLI versus MANDOL.
ARBLI vs MANDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cephalosporin antibiotic; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
10 mg orally once daily.
1-2 g IV or IM every 4-8 hours; maximum 12 g/day.
None Documented
None Documented
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
Clinical Note
moderateCefamandole + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefamandole."
Clinical Note
moderateCefamandole + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefamandole."
Clinical Note
moderateWarfarin + Cefamandole
"Warfarin may increase the anticoagulant activities of Cefamandole."
Clinical Note
moderatePhenprocoumon + Cefamandole
Terminal elimination half-life is 1.2-1.8 hours in adults with normal renal function; prolonged to 4-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and >12 hours in severe impairment (CrCl <30 mL/min).
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: 65-85% unchanged via glomerular filtration and tubular secretion; biliary/fecal: ~15-20% as active drug and metabolites; minor hepatic metabolism.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefamandole."